Search Results
Your search for ,maY matches 16609 pages
Showing 12651 - 12700Patient Expectations of Benefit in Early-phase Trials: Ethics Issues in Informed Consent
It has been found that many patients in early-phase oncology trials believe their chance of benefit to be much higher than estimates derived from historical data.1-3 In a recently reported study in Journal of Clinical Oncology, Kevin P. Weinfurt, PhD, of Duke Clinical Research Institute, and...
Expert Point of View: Sagar Lonial, MD
Commenting on Dr. Palumbo’s presentation at the ASH meeting, Sagar Lonial, MD, Professor of Hematology and Medical Oncology at the Winship Cancer Center at Emory University, Atlanta, noted that while a survival benefit has been associated with maintenance lenalidomide (Revlimid) after transplant,...
Survival Benefit Achieved with Four Drugs plus Maintenance in Myeloma
An overall survival benefit in newly diagnosed multiple myeloma was attained with a four-drug induction regimen followed by a duet for maintenance in a study from the Italian GIMEMA network. Antonio Palumbo, MD, Chief of the Myeloma Unit at the University of Torino in Italy, reported the findings...
Tremelimumab Not Better Than Standard-of-care Chemotherapy in Patients with Advanced Melanoma
Tremelimumab did not produce a statistically significant advantage in overall survival compared to first-line standard-of-care chemotherapy in a phase III randomized trial reported in the Journal of Clinical Oncology. At final analysis, median overall survival by intent to treat was 12.6 months...
SIDEBAR: Expect Questions from Patients with Diabetes and Cancer
Patients with diabetes and cancer need to know that some chemotherapy drugs and adjuvant agents may require modifications in how they manage their diabetes. For example, patients who are receiving steroids might have to further restrict their diet to keep blood sugar levels under control. “You...
Keeping Diabetes under Control Is Critical to Good Outcomes for Patients Who Also Have Cancer
In the News focuses on media reports that your patients may have questions about at their next visit. This continuing column will provide summaries of articles in the popular press that may prompt such questions, as well as comments from colleagues in the field. Cancer and diabetes can be comorbid...
Oncology Meetings
February Scripps Cancer Center’s 33rd Annual Clinical Hematology and Oncology ConferenceFebruary 16-19 • San Diego, CaliforniaFor more information:www.scripps.org/events/clinical-hematology-and-oncology-february-16-2013 2013 Translational Research Cancer Centers Consortium: The Power of Negative...
Betting Against the Odds
I knew the two tumors in my left breast were cancerous even before I got the pathology results back on my biopsy. I could clearly see the tumors on the digital mammogram my doctor ordered, and when the radiologist pointed out that they had spikes radiating from the edges and that he was scheduling...
Researchers Develop Automated Breast Density Test Linked to Cancer Risk
Researchers at Moffitt Cancer Center in Tampa, Florida, and colleagues at the Mayo Clinic in Rochester, Minnesota, have developed a novel computer algorithm to quantify breast density based on analysis of a screening mammogram. Increased levels of mammographic breast density have been shown in...
Turmeric
The use of dietary supplements by cancer patients has risen significantly over the past 2 decades despite insufficient evidence of safety and effectiveness. Finding reliable sources of information about dietary supplements can be daunting. Patients typically rely on family, friends, and the...
Subcutaneous Trastuzumab a Potential Alternative to Intravenous Administration in Breast Cancer
Subcutaneous administration of trastuzumab might offer improvements in patient convenience and resource use compared with conventional intravenous administration (Herceptin). A new subcutaneous trastuzumab formulation containing a fixed dose of 600 mg and recombinant human hyaluronidase PH-20...
The Doctor Who Championed Patient Navigation in Harlem
After completing his residency at Memorial Sloan-Kettering Cancer Center, Harold P. Freeman, MD, arrived at Harlem Hospital Center in 1967, where the overwhelming majority of his patients presented with late-stage disease. That early experience with underserved patients would shape his career as...
Gene in Eye Melanomas Linked to Good Prognosis
Melanomas that develop in the eye often are fatal. Now, researchers at Washington University School of Medicine and the Siteman Cancer Center, St. Louis, Missouri, report they have identified a mutated gene in melanoma tumors of the eye that appears to predict a good outcome. The research was...
International Members Cite Networking, Enhanced Patient Care Among Benefits of ASCO Membership
Thanks to the membership category ASCO designed for physicians in developing countries, Brazilian oncologist Milena Mak, MD, can greatly enhance the care she delivers in the very busy 580-bed Instituto do Cancer do Estado de Sao Paulo. And radiation oncologist Pooja Nandwani Patel, MD, can use the...
Research Roundup from San Antonio: New Data on Triple-negative, HER2-positive, Local, and Advanced Breast Cancer
The 2012 San Antonio Breast Cancer Symposium featured more than 2,500 abstracts and lectures, including timely research in the field and discussions for scientists and clinicians alike. In addition to nearly two dozen in-depth reports from the meeting, The ASCO Post brings readers the following...
Abiraterone in Patients with Metastatic Castration-resistant Prostate Cancer and No Prior Chemotherapy
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. Indication On December 10, 2012, abiraterone acetate (Zytiga)...
ASH Highlights Included New Data in Myeloma, Lymphoma, and Leukemia, plus Studies of Mucositis and Graft-vs-Host Disease
The 54th Annual Meeting of the American Society of Hematology (ASH) featured about 5,000 abstracts, including oral sessions and posters, as well as named lectures and symposia. In addition to our regular news coverage from the meeting, below are capsule summaries of a few news highlights that we...
Chemotherapy for Breast Cancer Carries a Small, but Concerning, Risk for Leukemia
The risk for developing a secondary malignancy after chemotherapy for breast cancer is very small, but it is statistically significantly higher than for the general population, a review of the National Comprehensive Cancer Network (NCCN) database revealed in a study presented at the 2012 San...
Expert Point of View: Sarah B. Goldberg, MD, MPH
In a commentary accompanying reporting of the phase II study of the MEK inhibitor selumetinib by Dr. Pasi A. Jänne, MD, PhD, and colleagues, Sarah B. Goldberg, MD, MPH, Assistant Professor of Medicine, and colleagues at Yale Cancer Center, New Haven, Connecticut, noted that KRAS, a member of the...
Expert Point of View: William G. Woods, MD
Press conference moderator William G. Woods, MD, Pediatric Hematology/Oncology Director and the Daniel P. Amos Children’s Chair, Aflac Cancer and Blood Disorders Center, Children’s Healthcare of Atlanta, called the phase III FRALLE trial “an important confirmatory step regarding the front-line...
Daunorubicin-free Induction Therapy for Standard-risk Childhood Acute Lymphoblastic Leukemia
Omitting daunorubicin from induction therapy for children with standard-risk acute B-cell lymphoblastic leukemia (ALL) does not compromise survival and at the same time reduces the risk of associated toxicities, including myelosuppression and cardiac damage, according to results of the large phase...
Expert Point of View: Farhad Ravandi, MD
Over the past 2 decades, we have witnessed remarkable progress in the treatment of patients with acute promyelocytic leukemia (APL). The introduction of all-trans retinoic acid (ATRA) in the front-line therapy setting and arsenic trioxide in the relapse setting had already led to a significant...
Chemotherapy-free Regimen Successful in Acute Promyelocytic Leukemia
For the first time, a chemotherapy-free regimen was superior to conventional cytotoxic chemotherapy for the treatment of acute promyelocytic leukemia (APL). The combination of all-trans retinoic acid (ATRA) plus arsenic trioxide (Trisenox) achieved significantly superior overall survival compared...
We Need Gemtuzumab Available Again to Treat AML
The word “revival” signifies a renewed use or acceptance after a period of inactivity; similarly, the word “resurrection” refers to the concept of an entity coming back to life after death. In the past year, these terms have been used frequently by us (and others) in articles calling for the return ...
Expert Point of View: Philip Agop Philip, MD and Alan P. Venook, MD
Philip Agop Philip, MD, Head of the Multidisciplinary Team for Gastrointestinal and Neuroendocrine Oncology and Neuroendocrine at Karmanos Cancer Institute at Wayne State University, Detroit, was the formal discussant of the paper at the Gastrointestinal Cancers Symposium. He said the positive...
Oncology Meetings
March Hematology and Medical Oncology Board Review: Contemporary Practice from Memorial Sloan-Kettering Cancer CenterMarch 1-5, 2013 • New York, New YorkFor more information: www.mskcc.org/hemoncreviewcourse International Congress on Targeted Anticancer TherapiesMarch 4-6 • Paris, FranceFor more...
Vemurafenib-resistant BRAF-mutant Melanoma
Mutational activation of BRAF is the most prevalent genetic alteration in melanoma, with ≥ 50% of tumors expressing the BRAF(V600E) oncoprotein. Vemurafenib (Zelboraf) produces tumor regression and improved survival in patients with late-stage BRAF-mutated melanoma. However, most patients relapse...
Solving a 30-year Mystery
When I began experiencing severe neck and back pain about 9 years ago, I had no idea it could be a late side effect from the radiation therapy I had received 31 years ago to treat my Hodgkin lymphoma. And none of the doctors I’ve seen over the past decade have been able to make the connection...
Genetics, Mathematics, and Colorectal Cancer
Two recent study reports in colorectal cancer explored new data on genetic precursors to the disease and outcome predictors once treatment is initiated. New Genetic Links to Colorectal Cancer Are Identified Investigators from Vanderbilt-Ingram Cancer Center, Nashville, and colleagues in China,...
SIDEBAR: Beta-adrenergic Signaling Pathway
The take-home message from this study is that in this large group of patients, we have found that beta-blocker intake during radiation therapy for non–small cell lung cancer (NSCLC) is associated with improved survival and reduced rates of tumor spread, even when controlling for a large number of...
Use of Beta-blockers Associated with Improved Survival in Patients with NSCLC Receiving Definitive Radiation Therapy
As reported recently in Annals of Oncology, a retrospective study by Wang and colleagues showed that use of beta-adrenergic receptor antagonists (beta-blockers), typically used in treatment of hypertension and heart disease, was associated with significantly improved distant metastasis–free...
More Brief Reports from ASH, Including New Data in Leukemia, Lymphoma, and Myelodysplastic Syndrome
At the 54th Annual Meeting of the American Society of Hematology (ASH), held in Atlanta, nearly 5,000 abstracts were presented in oral sessions and posters. As part of our ongoing comprehensive coverage from the meeting, here are several more studies of note. New Targets in Acute Myeloid Leukemia...
Expert Point of View: David J. Kuter, MD, PhD
David J. Kuter, MD, PhD, Professor of Medicine, Harvard Medical School, and Director of the Center for Hematology at Massachusetts General Hospital, Boston, commented on the findings for The ASCO Post. “TOPPS is a good attempt to address whether transfusions are helpful as prophylaxis in patients...
Make a Lasting Difference: Choose the Giving Option that Works for You
If you are like the many supporters of the Conquer Cancer Foundation, you may have reached a point where you would welcome the opportunity to influence not only the future ownership of your possessions, but the meaning that others assign to your life. One way to accomplish this is by considering...
Dose-dense Chemotherapy in Breast Cancer: Epirubicin-based Regimens Studied in German and UK Trials
In the treatment of early breast cancer, dose-dense regimens (given every 2 weeks) have proven superior to conventionally dosed chemotherapy (given every 3 weeks), but data on long-term survival are lacking. Two studies presented at the San Antonio Breast Cancer Symposium evaluated the benefit of...
Expert Point of View: Axel Grothey, MD and Eric Van Cutsem, MD, PhD
Two gastrointestinal cancer experts commented on the findings in interviews with The ASCO Post. Axel Grothey, MD, Professor of Oncology at the Mayo Clinic, Rochester, Minnesota, noted, “The PEAK and SPIRITT trial were decently designed, decently powered randomized phase II trials, and the results...
Outcomes Comparable for Panitumumab and Bevacizumab in Metastatic Colorectal Cancer
In patients with KRAS wild-type metastatic colorectal cancer, outcomes were comparable whether patients received the epidermal growth factor receptor (EGFR) inhibitor panitumumab (Vectibix) or the vascular endothelial growth factor (VEGF) inhibitor bevacizumab (Avastin). This was shown both in the...
On Radiation and Cancer Risk
We owe our life to radiation. The universe was created in a thermonuclear explosion, and continued existence of life on Earth depends on plants using chlorophyll to capture light energy emitted by the sun (and exploding supernovas) and converting it into chemical energy, with the subsequent...
Study Finds Young Cancer Survivors Often Skip Checkups
Athough the majority of the more than 69,000 adolescents and young adults (AYAs) diagnosed with cancer each year will survive their disease, many of them will experience interruptions in their education and a derailment in their career tract, curtailing their lifetime earning potential and reducing ...
FOLFOXIRI Plus Bevacizumab Is Superior to FOLFIRI Plus Bevacizumab in Metastatic Colorectal Cancer
For the treatment of metastatic colorectal cancer, better outcomes were achieved when bevacizumab (Avastin) was added to FOLFOXIRI (leucovorin, fluorouracil [5-FU], oxaliplatin, irinotecan), rather than FOLFIRI (leucovorin, 5-FU, irinotecan), in the phase III TRIBE trial conducted at 35 Italian...
PET/CT With 124I-Girentuximab Can Identify Clear Cell Renal Cell Carcinoma While Minimizing Invasive Diagnostic Risks
Positron-emission tomography/computed tomography (PET/CT) with iodine-124 (124I) –girentuximab “can accurately and noninvasively identify” clear cell renal cell carcinoma, according to a phase III multicenter study reported in the Journal of Clinical Oncology. In addition, “PET/CT with...
SIDEBAR: Ask Patients about Their Smoking Status
“Receiving a cancer diagnosis represents a ‘teachable moment’ for delivering smoking cessation and relapse prevention interventions,” concluded a study in the journal Cancer1 about smoking relapse in patients with thoracic cancer or head and neck cancer. Previous research by two of the study’s...
Patients with Cancer Need to Know That It Is Never Too Late to Quit Smoking
In the News focuses on media reports that your patients may have questions about at their next visit. This continuing column will provide summaries of articles in the popular press that may prompt such questions, as well as comments from colleagues in the field. Patients with head and neck or lung...
Fitness: Can Exercise Lengthen Survival in Patients with Cancer?
Regular physical activity has long been associated with decreased risk of disease, including many types of cancer. Such benefits may translate into increased life expectancy of up to 4.5 years, with even the lowest levels of activity providing some survival advantage.1 Most strikingly, however,...
SIDEBAR: Patient Information Available at Cancer.Net
Cancer.Net offers information written for patients on breast reconstruction and what to expect following a mastectomy. To obtain this information, you may wish to recommend your patients visit http://www.cancer.net/cancer-types/breast-cancer/treatment. Also, to learn more about ASCO programs for...
My Life Will Never Be Normal
After being diagnosed with stage II invasive ductal carcinoma in my right breast in 2004, I did an Internet search to learn more about my treatment options so I could be prepared when I met with my oncologist to discuss my treatment plan. I was especially interested in therapies that would be...
Expert Point of View: Nancy L. Keating, MD, MPH
By Nancy L. Keating, MD, MPH In this large study examining care for patients with a variety of tumor types in the Veterans Health Administration (VA), we found no clear association of tumor boards with better quality of care or outcomes. It is unclear if our findings can be generalized outside of...
Study Shows Little Association of Multidisciplinary Tumor Boards with Measures of Care
A survey of Veterans Affairs (VA) medical centers recently reported by Nancy L. Keating, MD, MPH, and colleagues at Harvard Medical School in the Journal of the National Cancer Institute showed that the presence of multidisciplinary tumor boards had little association with rates of recommended...
Oncology Meetings
March Emerging Trends Conference: Reactivation of Hepatitis BMarch 21-22 • Arlington, VirginiaFor more information: www.aasld.org/additionalmeetings/Pages/emergingtrends.aspx 5th Thyroid Neoplasms ConferenceMarch 21-23 • Houston, TexasFor more information: www.mdanderson.org/conferences Community...
IBM's Watson Goes Through Basic Training in Oncology
While IBM’s Watson supercomputer may have defeated two former champions on the TV game show Jeopardy! 2 years ago, it is now facing its greatest challenge yet: deciphering huge amounts of scientific data and interpreting clinical information to help oncologists make personalized evidence-based...
